Amneal Pharmaceuticals Q3 Adjusted Earnings, Revenue Rise

MT newswire2026/11/03 10:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

06:33 AM EST, 11/03/2026 (MT Newswires) -- Amneal Pharmaceuticals (AMRX) reported Q3 adjusted earnings Tuesday of $0.26 per share, up from $0.17 a year earlier. Analysts polled by FactSet expected $0.24. Net revenue for the quarter ended Sept. 30 was $862.7 million, compared with $784.5 million a year earlier. Analysts expected $817.8 million. For 2026, the company now expects adjusted diluted EPS of $1.04 to $1.08, compared with its prior guidance range of $0.96 to $1.06. Analysts expect $1.03. Amneal now projects full-year revenue between $3.15 billion and $3.25 billion, compared with its previous guidance range of $3.10 billion to $3.20 billion. Analysts are looking for $3.16 billion. The company's shares were down 1.1% in premarket activity.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.

华尔街见闻•2026/11/09 09:21